Overview

* Xilio Q3 collaboration revenue rises to $19.1 mln from $2.3 mln year-over-year

* Net loss for Q3 widens to $16.3 mln from $14.0 mln year-over-year

* Company anticipates cash runway into Q1 2027

Outlook

* Xilio plans to submit IND for XTX501 in mid-2026

* Company anticipates cash runway into Q1 2027

* Xilio seeks partner for vilastobart combination therapy

Result Drivers

* R&D expenses were $14.3 million for the quarter ended September 30, 2025, compared to $10.8 million for the quarter ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$16.29

Income mln

Q3 -$1.93

Income mln

from

Operatio

ns

Q3 $21 mln

Operatin

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Xilio Therapeutics Inc ( XLO ) is $2.00, about 61.3% above its November 12 closing price of $0.77

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)